P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
Year: 2017
Type: article
Source: Journal of Virus Eradication
Authors: Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih-Wei Lin, Yang Lei, Teresa I. Ng, Tami Pilot-Matias, Jens Kort, Federico Mensa
Institutions: The University of Texas at San Antonio Health Science Center, Texas Liver Institute, Hôpital Cochin, AbbVie (United States), Vall d'Hebron Hospital Universitari, Royal Adelaide Hospital, Université Paris-Est Créteil, Hôpitaux Universitaires Henri-Mondor, Piedmont HealthCare, Henry Ford Health, Caulfield Hospital, University of North Carolina at Chapel Hill, North Shore University Hospital
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W3041718414